Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Change in Accured Expenses (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Change in Accured Expenses for 2 consecutive years, with -$1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 103.81% to -$1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a N/A change, with the full-year FY2025 number at $1.5 million, up 435.05% from a year prior.
  • Change in Accured Expenses was -$1.6 million for Q4 2025 at Neuphoria Therapeutics, down from $718261.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q2 2025 to a low of -$1.6 million in Q4 2025.